Comments
Glenmark Pharmaceuticals Ltd has received final approval from the US Food and Drug Administration (USFDA) for fluphenazine hydrochloride tablets USP in strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg. These tablets are the generic version of Prolixin tablets manufactured by Apothecon Inc.
Glenmark Pharmaceuticals Inc, USA, will handle the distribution of the fluphenazine hydrochloride tablets in the US.
As per IQVIATM sales data for the 12-month period ending September 2023, r Prolixin tablets recorded annual sales of about $18.1 million. Glenmark currently holds a portfolio of 189 products authorised for distribution in the US market, with 50 ANDAs pending approval by the USFDA.
The shares were up by 0.45 per cent to Rs 759 at 3 pm on BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.